Tag - AXSM

Axsome Therapeutics

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

Axsome Therapeutics

Axsome Therapeutics names David Marek as CCO

Axsome Therapeutics (NASDAQ:AXSM) has appointed David Marek as chief commercial officer, effective Aug. 31. Mr. Marek joins Axsome from Amgen (NASDAQ:AMGN), where he was most recently VP and general manager of the...

Axsome Therapeutics

SVB Leerink starts Axsome Therapeutics at OP; PT $25

SVB Leerink initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and $25 price target. The stock closed at $14.50 on April 5. “The specialty pharma business model (using proprietary...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.